Bill Maloney Appointed as Texas Market Lead and Dallas Office Managing Partner at CrossCountry Consulting
As we continue to expand our presence in the Texas market, Bill's expertise and strategic vision will be pivotal in driving our growth and delivering exceptional service to our clients.
Maloney brings more than 25 years of distinguished experience across financial, operational, and strategic leadership roles. His depth of knowledge spans key areas such as US GAAP and IFRS accounting, financial reporting, business growth strategies, and internal controls. Maloney's extensive experience in steering teams through significant business transformations and intricate financial reporting complexities sets the stage for the firm's accelerated growth in the Texas market.
'Bill is an outstanding addition to CrossCountry Consulting,' said Erik Linn, Co-Founder and Managing Partner at CrossCountry Consulting. 'His wealth of experience, proven leadership, and dedication to helping clients solve complex challenges align perfectly with our commitment to excellence. Bill also embodies the collaborative and people-focused culture that CrossCountry values, making him an ideal fit for our team. As we continue to expand our presence in the Texas market, Bill's expertise and strategic vision will be pivotal in driving our growth and delivering exceptional service to our clients.'
Prior to joining CrossCountry Consulting, Maloney held several senior leadership roles, including serving as the National Practice Leader of Financial Advisory Services and Chief Operating Officer of Advisory Services at Riveron. He also held the position of Vice President of Reporting and Technical Accounting at Orthofix International and spent nearly 13 years at PwC, where he gained extensive experience in audit, transaction services, and global accounting consulting.
'I am excited to join CrossCountry Consulting and contribute to the firm's growth in the Texas market,' said Maloney. 'Their reputation for delivering top-tier advisory services, continued investment in their people, and commitment to innovation and client success, creates immense potential for growth and positive impact within the Texas market. I look forward to working closely with our talented teams and helping clients achieve their strategic objectives.'
CrossCountry Consulting officially opened an office in Dallas in early 2024 in response to greater market demand across the Southwest region. They have been steadily adding clients and hiring team members in Texas for the past several years – leveraging their teams in Dallas-Fort Worth, Houston metro, and Austin-San Antonio to serve companies across the region.
Learn more about CrossCountry Consulting.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
Leveragen and Propeller Bio Announce Strategic Collaboration to Advance Antibody and Protein Therapeutics
BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Leveragen, a Boston-based biotechnology company pioneering next-generation in vivo antibody discovery platforms, announced today a strategic collaboration with Propeller Bio, a newly launched biotechnology company focused on antibody and protein-based therapeutics. As part of the partnership, Propeller Bio will support the continued development of Leveragen's antibody discovery platforms through a strategic investment. In turn, Propeller will collaborate closely with Leveragen and gain access to Leveragen's full suite of proprietary antibody mouse models, including the Singularity Sapiens Mouse, the industry-leading fully human single-domain antibody discovery platform. 'Leveragen's Singularity Sapiens Mouse is a differentiated platform for antibody discovery, It provides a unique option for high-quality, in vivo matured human VH domains with impressive diversity and developability." - Dr. David Shen, CEO of Propeller Bio Share The Singularity Sapiens Mouse is engineered to produce robust immune responses across a broad range of antigens, enabling efficient discovery of fully human VH-only antibodies with strong developability and diverse epitope coverage. The platform supports multiple therapeutic formats, including bispecifics, antibody-drug conjugates, CAR-T therapies, and mRNA-encoded antibodies, making it a versatile tool for biologics development. 'We're excited to collaborate with Dr. David Shen and the team at Propeller Bio,' said Weisheng Chen, PhD, Founder and CEO of Leveragen. 'David has a remarkable track record of bringing innovative biomedicines to patients in need. We believe Propeller Bio is well positioned to lead the next wave of therapeutic breakthroughs, and we're proud to support their work with our cutting-edge antibody discovery platforms.' David W. Shen, PhD, Founder and CEO of Propeller Bio, is a widely recognized leader in antibody and protein therapeutics. He previously held senior leadership roles at Amgen, Merck, Teva, and NGM Bio. Most recently, he was Founder and CEO of Proteologix, a leader in the development of bispecific antibodies for immune-mediated diseases. In less than three years since inception, the company was acquired by Johnson & Johnson for $850 million upfront and an undisclosed milestone payment in 2024. 'Leveragen's Singularity Sapiens Mouse is a differentiated platform for antibody discovery,' said Dr. Shen. 'It provides a unique option for high-quality, in vivo matured human VH domains with impressive diversity and developability. This platform presents a compelling alternative to camelid immunization or synthetic libraries, offering speed, flexibility, and translational relevance. It gives us a solid foundation for building a differentiated pipeline.' This collaboration highlights Leveragen's growing role as a trusted discovery partner for biotech companies pushing the frontiers of biologics innovation. About Leveragen Leveragen is a biotech company based in Woburn, Massachusetts, focused on accelerating biologics innovation through next-generation in vivo discovery platforms. Its Singularity Suite includes a collection of genetically engineered mouse models capable of generating exclusively single-domain antibodies from the VH repertoires of humans, mice, and companion animals. These platforms support the development of advanced therapeutic modalities, including bispecifics, ADCs, mRNA-encoded antibodies, targeted drug delivery, and cell therapies. Leveragen's technologies are trusted by leading biotech and pharmaceutical companies around the world. LinkedIn About Propeller Bio Propeller Bio is founded by David Shen along with a group of seasoned biotech entrepreneurs with a proven track record of success. Supported by leading investors, the company focuses on discovering and developing innovative biologic therapeutics designed to safely and effectively target multiple disease-driving pathways, aiming for synergistic effects to treat patients with unmet medical needs. The organization boasts a diverse team with extensive expertise in drug discovery and development, and is based in the Bay Area, California.
Business Wire
7 minutes ago
- Business Wire
Venova Technologies Awarded $2.23M SBIR Phase II Grant From NIH For Novel Contraceptive Device
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Venova Technologies, Inc., a women-led startup developing a novel long-acting, hormone-free and copper-free female birth control device, has been awarded a $2.23M Small Business Innovation Research (SBIR) Phase II Grant from the National Institutes of Health (NIH). The SBIR program is a highly competitive, awards-based program designed to stimulate technological innovations developed by U.S. small businesses on a path to commercialization. This Phase II award accelerates the preclinical development of Venova's innovative cervical barrier device toward first-in-human clinical studies and brings the company's total funding to over $5M. According to a UCLA survey, 73% of women want a birth control method that is very effective and has limited side effects, but this does not currently exist. A 2023 study found that half of women will stop or switch their birth control method because of unwanted or adverse side effects. 'This award is a pivotal milestone that brings us one step closer to offering a new birth control option for women that is designed to be side-effect-free and addresses concerns of pain from IUD insertion,' said Emily Man, Co-Founder & CEO of Venova. 'Validation from the scientific community highlights the growing momentum and critical need for innovation in women's health.' 'It's more important than ever to provide a wide range of choices for contraception that can meet the needs of more patients,' said Dr. Katharine White, Chair of Obstetrics and Gynecology at Boston University Chobanian & Avedisian School of Medicine and Chief of Obstetrics and Gynecology for the Boston Medical Center Health System. Dr. White is also the Chief Medical Advisor at Venova. 'Offering more affordable options that address a variety of preferences will enable more women to achieve the family size that they truly desire.' About Venova Technologies Venova Technologies, Inc., is a women-led startup dedicated to empowering women to take full control over their reproductive health. The company is developing a novel long-acting female contraceptive barrier device. Headquartered in Cambridge, Mass., at The Engine built by MIT, Venova participates in this premier ecosystem for high-potential, Tough Tech startups. For more information, visit Follow Venova on LinkedIn at
Business Wire
7 minutes ago
- Business Wire
Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the 'Investor Relations' section of the Establishment Labs website at About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO 13485:2016 and FDA 21 CFR 820. Please visit our website for additional information at
